Paratek Corp., Nabriva Therapeutics, and Cempra all appear on course to bring new antibiotics to market soon. But which could be the best bet for your portfolio now?
News & Analysis: Cempra
The pharmaceutical company received an FDA rejection of the worst kind.
The biotech receives an analyst downgrade ahead of an FDA decision.
The industry leaders' mistakes are lessons for investors.
FDA uncertainty plagues the biotech's share price.
The biotech isn't having a good week.
A manufacturing delay has investors reassessing the biotech's current value.
These three companies have wagered millions on moonshot concepts.
Here's a look at the reasons why shares of Cempra jumped last month.
Selling shares at a discount will do that.